[Federal Register: May 5, 1999 (Volume 64, Number 86)]
[Notices]               
[Page 24167]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr05my99-71]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

 
Statement of Organization, Functions, and Delegations of 
Authority

    Part N, National Institutes of Health, of the Statement of 
Organization, Functions, and Delegations of Authority for the 
Department of Health and Human Services (40 FR 22859, May 27, 1975, as 
amended most recently at 64 FR 8583, February 22, 1999, and 
redesignated from Part HN as Part N at 60 FR 56605, November 9, 1995), 
is amended as set forth below to reorganize the Office of Disease 
Prevention (ODP) as follows: (1) Abolish the Division of Disease 
prevention, ODP, and transfer its functions to the ODP and (2) revise 
the functional statement of the ODP.
    Section N-B, Organization and Functions, under the heading Office 
of the Director (NA, formerly HNA), Office of Disease Prevention (NA2, 
formerly HNA2) is amended as follows:
    (1) The title and functional statement of the Division of Disease 
Prevention (NA22, formerly HNA22) are abolished in their entirety.
    (2) The functional statement for the Office of Disease Prevention 
(NA2, formerly HNA2) is replaced with the following:
    Office of Disease Prevention (NA2, formerly HNA2). Coordinates the 
activities of disease prevention, rare diseases, dietary supplements, 
and medical applications of research, and advises the NIH Director and 
senor staff on the following: (a) research related to disease 
prevention, and promotion of disease prevention research; (b) research 
related to dietary supplements and their role in disease prevention; 
(c) research and activities related to rare diseases; and (d) medical 
applications of research including drugs, procedures, devices and other 
technology developed from basic biomedical research at NIH. The Office 
also: (1) Advises the Associate Director for Disease Prevention and 
provides guidance to the research institutes on research related to 
disease prevention; (2) coordinates and facilitates the systematic 
identification of research activities pertinent to all aspects of 
disease prevention, including: (a) identification of risk factors for 
disease; (b) risk assessment, identification, and development of 
biologic, environmental, and behavioral interventions to prevent 
disease occurrence or progression of presymptomatic disease; and (c) 
the conduct of field trials and demonstrations to assess interventions 
and encourage their adoption, if warranted; (3) identifies, 
coordinates, and encourages fundamental research aimed at elucidating 
the chain of causation of acute and chronic diseases; (4) coordinates 
and facilitates clinically relevant NIH-sponsored research bearing on 
disease prevention, including interventions to prevent the progression 
of detectable but asymptomatic disease; (5) promotes the coordinating 
linkage for research institutes on biobehavioral modification toward 
prevention of disease; (6) coordinates with the Office of Medical 
Applications of Research to promote the effective transfer of 
identified safe and efficacious preventive interventions to the health 
care community and the public; (7) works with the research institutes 
to initiate and develop FRAs, PAs, and FFPs to enhance disease 
prevention program development; and sponsors singly or in combination 
with other organizations, workshops and conferences on disease 
prevention; (8) provides a link between the disease prevention and 
health promotion activities of the research institutes of the NIH, the 
Surgeon General and Assistant Secretary for Health, and the Secretary, 
DHHS; (9) monitors the effectiveness and progress of disease prevention 
and health promotion activites of the NIH; and (10) reports 
expenditures and personnel involved in prevention activities at NIH.
    Delegations of Authority Statement: All delegations and 
redelegations of authority to offices and employees of NIH which were 
in effect immediately prior to the effective date of this 
reorganization and are consistent with this reorganization shall 
continue in effect, pending further redelegation.

    Dated: April 22, 1999.
Ruth L. Kirschstein,
Acting Director, National Institutes of Health.
[FR Doc. 99-11208 Filed 5-4-99; 8:45 am]
BILLING CODE 4140-01-M